Splicing Factor 3a Subunit 1 Promotes Colorectal Cancer Growth via Anti-Apoptotic Effects of Syntaxin12
Authors:
- Takahiro SasakiTSTakahiro Sasaki
- Hiroaki KonishiHKHiroaki Konishi
- Tatsuya DokoshiTDTatsuya Dokoshi
- Aki SakataniASAki Sakatani
- Hiroki TanakaHTHiroki Tanaka
- Koji YamamotoKYKoji Yamamoto
- Keitaro TakahashiKTKeitaro Takahashi
- Katsuyoshi AndoKAKatsuyoshi Ando
- Nobuhiro UenoNUNobuhiro Ueno
- Shin KashimaSKShin Kashima
- Kentaro MoriichiKMKentaro Moriichi
- Hiroki TanabeHTHiroki Tanabe
Open Access
- 24 January 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1195
Abstract
RNA dysregulation mediated by aberrant RNA-binding proteins (RBPs) is closely associated with tumorigenesis. However, the tumorigenic mechanisms of each RBP remained unclear. In this study, we demonstrate that downregulation of Splicing factor 3A1 (SF3A1) markedly suppressed the proliferation of colorectal cancer (CRC) cells, with minimal cytotoxicity observed in non-cancerous epithelial cells. The tumor-promoting function of SF3A1 was further validated in an HCT116 xenograft mouse model. Multiple apoptosis assays—including TdT-mediated dUTP nick end labeling (TUNEL) staining, poly-ADP-ribose polymerase (PARP) immunoblotting, and caspase-3/7 activity measurements—showed that SF3A1 inhibited apoptotic signaling in CRC cells. Transcriptome analysis, combined with RNA-immunoprecipitation (RIP), identified Syntaxin 12 (STX12) as a downstream effector of SF3A1. Knockdown of STX12 induced apoptosis in CRC cells but had no effect on the viability of non-cancerous HCEC-1CT epithelial cells. Furthermore, STX12 mRNA levels were significantly reduced following SF3A1 knockdown, indicating that SF3A1-mediated stabilization of STX12 contributes to apoptosis resistance in CRC cells. Collectively, our findings establish that SF3A1 promotes CRC progression by stabilizing STX12 mRNA and selectively inhibiting apoptosis in malignant cells, thereby identifying the SF3A1–STX12 regulatory axis as a novel and selective therapeutic target for CRC.Keywords
All Related Versions
Funding Information
- Japan Society for the Promotion of Science (21K07929)
- Japan Society for the Promotion of Science (22K15363)
- Japan Society for the Promotion of Science (21KK0291)
- Japan Society for the Promotion of Science (22K08047)
- Intractable Disease Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare (none)
- Suhara Memorial Foundation (none)
This publication has 32 references indexed in Scilit:
- Structural basis for the interaction between the first SURP domain of the SF3A1 subunit in U2 snRNP and the human splicing factor SF1Protein Science, 2022
- Testis‐specific hnRNP is expressed in colorectal cancer cells and accelerates cell growth mediating ZDHHC11 mRNA stabilizationCancer Medicine, 2022
- New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancerCancer Communications, 2022
- A tumor-specific modulation of heterogeneous ribonucleoprotein A0 promotes excessive mitosis and growth in colorectal cancer cellsCell Death & Disease, 2020
- Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancerPharmacology & Therapeutics, 2019
- LncRNA: Shedding light on mechanisms and opportunities in fibrosis and agingAgeing Research Reviews, 2019
- RNA-Binding Proteins in Cancer: Old Players and New ActorsTrends in Cancer, 2017
- microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNABiochemical and Biophysical Research Communications, 2015
- microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1Oncogene, 2013
- The eukaryotic nucleotide excision repair pathwayBiochimie, 2003